Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Resch, B; Eber, E; Ehringer-Schetitska, D; Kiechl-Kohlendorfer, U; Michel-Behnke, I; Popow-Kraupp, T; Redlberger-Fritz, M; Seidel, M; Strenger, V; Wald, M; Zacharasiewicz, A; Berger, A.
Respiratory Syncytial Virus Prophylaxis with Palivizumab 2019 Update of the Recommendations of the Austrian Association of Pediatric and Adolescent Medicine
PADIATR PADOL. 2019;
Doi: 10.1007/s00608-019-00725-9
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Resch Bernhard
- Co-authors Med Uni Graz
- Eber Ernst
- Seidel Markus
- Strenger Volker
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- During a round-table discussion by independent experts the 2008 recommendations for respiratory syncytial virus (RSV) prophylaxis with palivizumab by the Austrian Society of Pediatric and Adolescent Medicine were revised and an update for 2019 was created using the Delphi method. Preterm (PT) infants <= 28 (+6 days) weeks' gestational age (GA) should receive palivizumab for the first season (<9 months of age at the beginning of the season) with cessation at the end of the season. Infants at 29 (+0)-32 (+6) weeks' GA receive palivizumab for a first season (<6 months of age) if there is a positive RSV risk score of at least 4 points; and infants 33 (+0) to 35 (+6) weeks' GA (<3 months of age at the beginning of the season) for the first season if there is a positive RSV risk score of at least 4 points. Infants with bronchopulmonary dysplasia (BPD; oxygen requirement or need for ventilator support at 36 weeks' GA) should receive palivizumab for the first season, and in the case of BPD requiring treatment in the second year of life, also for a second season. All children with hemodynamically significant congenital heart disease (CHD) receive palivizumab prophylaxis for the first season, and only after discussion of the individual cases (partially corrected CHD or heart transplant), for a second season. Beyond the regulations, the experts recommend palivizumab for pulmonary indications, neuromuscular impairment, Down syndrome, immune deficiency syndromes, and severe immune suppression for the first RSV season. Palivizumab is given intramuscularly at a dosage of 15 & x202f;mg/kg a maximum of five times from the middle to end of November until March at intervals of 28 to 30 days. Common colds are not a contraindication to immunization. Palivizumab does not suppress the immune response following active immunization either.
- Find related publications in this database (Keywords)
- Bronchiolitis
- Preterm infants
- Bronchopulmonary dysplasia
- Congenital heart disease
- Consensus